Yoojin Sohn
Endocrinology, Diabetes & Metabolism · Stockbridge, GANPI 1548624869
Payments from drug & device makers
Across 161 payments — averaging $23.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$421
- Novo Nordisk$374
- Cequr Corporation$279
- Xeris Pharmaceuticals, Inc.$275
- Corcept Therapeutics$259
- Medtronic$246
- plus $2K from 29 others
What the payments were for
- Food & beverage$3,65998%
- Education$872%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 21 | $421 |
| Novo Nordisk | 23 | $374 |
| Cequr Corporation | 3 | $279 |
| Xeris Pharmaceuticals, Inc. | 13 | $275 |
| Corcept Therapeutics | 10 | $259 |
| Medtronic(2 entities) | 4 | $246 |
| Sanofi-aventis U.S. LLC | 8 | $202 |
| Mannkind Corporation | 8 | $174 |
| Lilly USA, LLC | 9 | $159 |
| Dexcom, Inc. | 7 | $147 |
| Tandem Diabetes Care, Inc. | 5 | $125 |
| Boehringer Ingelheim | 6 | $119 |
| AbbVie | 6 | $94 |
| BETA Bionics, Inc. | 2 | $92 |
| Ascensia Diabetes Care US Inc. | 4 | $83 |
| Abbott | 4 | $79 |
| Ionis Pharmaceuticals, Inc. | 3 | $64 |
| Insulet Corporation | 3 | $63 |
| Radius Health, Inc. | 1 | $51 |
| Sequel Med Tech, LLC | 2 | $47 |
| Pfizer | 2 | $43 |
| GSK | 2 | $36 |
| AstraZeneca(2 entities) | 2 | $35 |
| Averitas Pharma Inc. | 1 | $30 |
| Bayer | 2 | $29 |
| Rhythm Pharmaceuticals, Inc. | 1 | $29 |
| Recordati_rare_diseases_inc. | 1 | $26 |
| Madrigal Pharmaceuticals | 1 | $25 |
| IBSA Pharma Inc. | 1 | $21 |
| Acella Pharmaceuticals, LLC | 1 | $21 |
| Vivus LLC | 1 | $21 |
| Ascendis Pharma Endocrinology Inc | 1 | $20 |
| Kyowa Kirin, Inc. | 1 | $20 |
| Amneal Pharmaceuticals LLC | 1 | $19 |
| Organon | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CeQur Simplicity$176
- MINIMED 780G$133
How this compares
$3,746 in reported general payments places this provider in the 50th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
See all endocrinology, diabetes & metabolism providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 180 | $252,020 |
| JardianceEmpagliflozin | 56 | $74,345 |
| MounjaroTirzepatide | 58 | $66,955 |
| FarxigaDapagliflozin Propanediol | 38 | $46,398 |
| Tresiba Flextouch U-100Insulin Degludec | 64 | $38,949 |
| TrulicityDulaglutide | 26 | $29,415 |
| Tresiba Flextouch U-200Insulin Degludec | 39 | $28,319 |
| JanuviaSitagliptin Phosphate | 29 | $26,801 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 11 | $16,650 |
| Cequr SimplicityBolus Insulin Pump, 200 Unit | 28 | $13,408 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 89 | $11,172 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $10,816 |
| Humalog Kwikpen U-100Insulin Lispro | 43 | $10,204 |
| Novolog FlexpenInsulin Aspart | 49 | $10,069 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 14 | $10,044 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $374 | $258,229198 claims |
| Lilly USA, LLCMounjaro, Trulicity | $159 | $96,37084 claims |
| Boehringer IngelheimJardiance | $119 | $74,34556 claims |
| AstraZenecaFarxiga | $35 | $46,39838 claims |
| Cequr CorporationCequr Simplicity | $279 | $13,40828 claims |
| AbbVieSynthroid | $94 | $4,45044 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $19 | $2,187171 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
Other endocrinology, diabetes & metabolism in Stockbridge
- Shehzad TopiwalaStockbridge$172K
- Bruce BodeAtlanta$18.3M
- Gulliermo UmpierrezAtlanta$6.6M
- John ReedRoswell$5.7M
- Thomas JonesMacon$4.8M
- Steven LeichterColumbus$3.1M
- Jason BernerJasper$2.6M
- Ashwini GoreMacon$2.6M
- Adeniyi OdugbesanLawrenceville$1.8M
- David RobertsonAtlanta$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.